메뉴 건너뛰기




Volumn 24, Issue 6, 2015, Pages 677-685

Ex vivo expanded mesenchymal stromal cell minimal quality requirements for clinical application

Author keywords

[No Author keywords available]

Indexed keywords

BIOSAFETY; CARCINOGENESIS; CELL COUNT; CELL COUNTING; CELL EXPANSION; CELL GROWTH; CELL ISOLATION; CELL STRUCTURE; CELL THERAPY; EX VIVO STUDY; GOOD MANUFACTURING PRACTICE; GROWTH RATE; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; REVIEW; VALIDATION PROCESS; CLINICAL TRIAL (TOPIC); CYTOLOGY; IN VITRO STUDY; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PROCEDURES; QUALITY CONTROL; STANDARDS;

EID: 84924366186     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2014.0299     Document Type: Review
Times cited : (75)

References (56)
  • 1
    • 84924400067 scopus 로고    scopus 로고
    • Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Union L. Accessed January 07, 2014
    • Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Official J. Eur. Union L 324. Available at http://eurlex.europa.eu/LexUr iServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF. Accessed January 07, 2014.
    • Official J. Eur. , vol.324
  • 2
    • 84924400066 scopus 로고    scopus 로고
    • Annex 1: Manufacture of Sterile Medicinal Products. Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC
    • EudraLex. Volume 4: EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Annex 1: Manufacture of Sterile Medicinal Products (2008). Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC. Available at http://ec.europa.eu/health/documents/eudralex/vol-4/index-en.htm
    • (2008) EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use , vol.4
  • 3
    • 84999999641 scopus 로고    scopus 로고
    • Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1)
    • European Commission. (2010). Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use, the notification of substantial amendments and the declaration of the end of the trial (CT-1). Official Journal of the European Union 2010/C 82/01. Available at http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.C-.2010.082.01.0001.01.ENG
    • (2010) Official Journal of the European Union 2010/C 82/01
  • 5
    • 84876536833 scopus 로고    scopus 로고
    • Therapeutic potential of mesenchymal stem cells in regenerative medicine
    • Patel DM, J Shah and AS Srivastava. (2013). Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int 2013:496218.
    • (2013) Stem Cells Int , vol.2013 , pp. 496218
    • Patel, D.M.1    Shah, J.2    Srivastava, A.S.3
  • 6
    • 77952805220 scopus 로고    scopus 로고
    • Human mesenchymal stem cells and their use in cell-based therapies
    • Motaln H, C Schichor and TT Lah. (2010). Human mesenchymal stem cells and their use in cell-based therapies. Cancer 116:2519-2530.
    • (2010) Cancer , vol.116 , pp. 2519-2530
    • Motaln, H.1    Schichor, C.2    Lah, T.T.3
  • 7
    • 84862702680 scopus 로고    scopus 로고
    • Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications
    • Yi T and SU Song. (2012). Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 35:213-221.
    • (2012) Arch Pharm Res , vol.35 , pp. 213-221
    • Yi, T.1    Song, S.U.2
  • 8
    • 84893347301 scopus 로고    scopus 로고
    • Mesenchymal stem cells for regenerative therapy: Optimization of cell preparation protocols
    • Ikebe C and K Suzuki. (2014). Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols. Biomed Res Int 2014:951512.
    • (2014) Biomed Res Int , vol.2014 , pp. 951512
    • Ikebe, C.1    Suzuki, K.2
  • 9
    • 84898466874 scopus 로고    scopus 로고
    • Mesenchymal stem cells: Immune evasive, not immune privileged
    • Ankrum JA, JF Ong and JM Karp. (2014). Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 32:252-260.
    • (2014) Nat Biotechnol , vol.32 , pp. 252-260
    • Ankrum, J.A.1    Ong, J.F.2    Karp, J.M.3
  • 10
    • 2342482526 scopus 로고    scopus 로고
    • Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
    • Le Blanc K, I Rasmusson, B Sundberg, C Götherström, M Hassan, M Uzunel and O Ringdén. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441.
    • (2004) Lancet , vol.363 , pp. 1439-1441
    • Le Blanc, K.1    Rasmusson, I.2    Sundberg, B.3    Götherström, C.4    Hassan, M.5    Uzunel, M.6    Ringdén, O.7
  • 13
    • 84922568930 scopus 로고    scopus 로고
    • Standardization of good manufacturing practicecompliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications
    • Wuchter P, K Bieback, H Schrezenmeier, M Bornhäuser, LP Müller, H Bönig, W Wagner, R Meisel, P Pavel, et al. (2015). Standardization of good manufacturing practicecompliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy 17:128-139.
    • (2015) Cytotherapy , vol.17 , pp. 128-139
    • Wuchter, P.1    Bieback, K.2    Schrezenmeier, H.3    Bornhäuser, M.4    Müller, L.P.5    Bönig, H.6    Wagner, W.7    Meisel, R.8    Pavel, P.9
  • 14
    • 84924400064 scopus 로고    scopus 로고
    • Annex 2: Manufacture of Biological active substances and Medicinal Products for Human Use. Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC
    • EudraLex. Volume 4: EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use. Annex 2: Manufacture of Biological active substances and Medicinal Products for Human Use (2013). Directives 91/356/EEC, as amended by Directive 2003/94/EC, and 91/412/EEC. Available at http://ec.europa.eu/health/documents/eudralex/vol-4/index-en.htm
    • (2013) EU Guidelines to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use , vol.4
  • 16
    • 40949143606 scopus 로고    scopus 로고
    • Concise review: Isolation and characterization of cells from human term placenta: Outcome of the first international workshop on placenta derived stem cells
    • Parolini O, F Alviano, GP Bagnara, G Bilic, HJ Bühring, M Evangelista, S Hennerbichler, B Liu, M Magatti, et al. (2008). Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. Stem Cells 26:300-311.
    • (2008) Stem Cells , vol.26 , pp. 300-311
    • Parolini, O.1    Alviano, F.2    Bagnara, G.P.3    Bilic, G.4    Bühring, H.J.5    Evangelista, M.6    Hennerbichler, S.7    Liu, B.8    Magatti, M.9
  • 18
    • 84900517225 scopus 로고    scopus 로고
    • Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices
    • Sharma RR, K Pollock, A Hubel and D McKenna. (2014). Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices. Transfusion 54:1418-1437.
    • (2014) Transfusion , vol.54 , pp. 1418-1437
    • Sharma, R.R.1    Pollock, K.2    Hubel, A.3    McKenna, D.4
  • 19
    • 43049151898 scopus 로고    scopus 로고
    • Concise review: Wharton's jelly-derived cells are a primitive stromal cell population
    • Troyer DL and ML Weiss. (2008). Concise review: Wharton's jelly-derived cells are a primitive stromal cell population. Stem Cells 26: 591-599.
    • (2008) Stem Cells , vol.26 , pp. 591-599
    • Troyer, D.L.1    Weiss, M.L.2
  • 20
    • 84924354100 scopus 로고    scopus 로고
    • Human term placental cells: Phenotype, properties and new avenues in regenerative medicine
    • Caruso M, M Evangelista and O Parolini. (2012). Human term placental cells: phenotype, properties and new avenues in regenerative medicine. Int J Mol Cell Med 1:64-74.
    • (2012) Int J Mol Cell Med , vol.1 , pp. 64-74
    • Caruso, M.1    Evangelista, M.2    Parolini, O.3
  • 22
    • 33745437684 scopus 로고    scopus 로고
    • Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue
    • Kern S, H Eichler, J Stoeve, H Klüter and K Bieback. (2006). Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 24:1294-1301.
    • (2006) Stem Cells , vol.24 , pp. 1294-1301
    • Kern, S.1    Eichler, H.2    Stoeve, J.3    Klüter, H.4    Bieback, K.5
  • 23
    • 80052642226 scopus 로고    scopus 로고
    • Human adipose-derived stromal cells efficiently support hematopoiesis in vitro and in vivo: A key step for therapeutic studies
    • De Toni F, S Poglio, AB Youcef, B Cousin, F Pflumio, P Bourin, L Casteilla and P Laharrague. (2011). Human adipose-derived stromal cells efficiently support hematopoiesis in vitro and in vivo: a key step for therapeutic studies. Stem Cells Dev 20:2127-2138.
    • (2011) Stem Cells Dev , vol.20 , pp. 2127-2138
    • De Toni, F.1    Poglio, S.2    Youcef, A.B.3    Cousin, B.4    Pflumio, F.5    Bourin, P.6    Casteilla, L.7    Laharrague, P.8
  • 24
    • 84866239471 scopus 로고    scopus 로고
    • Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells
    • Strioga M, S Viswanathan, A Darinskas, O Slaby and J Michalek. (2012). Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev 21:2724-2752.
    • (2012) Stem Cells Dev , vol.21 , pp. 2724-2752
    • Strioga, M.1    Viswanathan, S.2    Darinskas, A.3    Slaby, O.4    Michalek, J.5
  • 26
    • 84924408482 scopus 로고    scopus 로고
    • Implementing directive 2004/23/EC of the European parliament and of the council as regards certain technical requirements for the donation, procurement and testing AU8c of human tissues and cells
    • European Commission Directive 2006/17/EC of 8 February
    • European Commission Directive 2006/17/EC of 8 February 2006. Implementing Directive 2004/23/EC of the European Parliament and of the Council as Regards Certain Technical Requirements for the Donation, Procurement and Testing AU8c of Human Tissues and Cells. Official Journal of the European Union L 38/40. Available at http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2006:038:TOC
    • (2006) Official Journal of the European Union L 38/40
  • 27
    • 0003975349 scopus 로고    scopus 로고
    • Commission Directive 2006/86/EC of 24 October. Implementing Directive 2004/23/ECof the European Parliament and of the Council As Regards Traceability Requirements, Notification of Serious Adverse Reactions and Events and Certain Technical Requirements for the Coding, Processing, Preservation, Storage and Distribution of HuAU8cman Tissues and Cells
    • Commission Directive 2006/86/EC of 24 October 2006. Implementing Directive 2004/23/ECof the European Parliament and of the Council As Regards Traceability Requirements, Notification of Serious Adverse Reactions and Events and Certain Technical Requirements for the Coding, Processing, Preservation, Storage and Distribution of HuAU8cman Tissues and Cells. Official Journal of the European Union L 294/32. Available at http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2006:294:TOC
    • (2006) Official Journal of the European Union L 294/32
  • 28
    • 84923080928 scopus 로고    scopus 로고
    • EMA/CHMP/BWP/457920/2012 rev 1
    • European Medicines Agency (EMA)/Committee for Medicinal Products for Human Use (CHMP) Guideline on the use of bovine serum in the manufacture of human biological medicinal products 2013. EMA/CHMP/BWP/457920/2012 rev 1. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-000351.jsp&mid=WC0b01ac058002956c
    • (2013) Guideline on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products
  • 29
    • 84924421268 scopus 로고    scopus 로고
    • Note for guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products
    • EMA/410/01 rev.3
    • European Medicines Agency (EMA)/European Commission. (2011). Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Human and Veterinary Medicinal Products. EMA/410/01 rev.3. Official Journal of the European Union C 73/01. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general-content-00351.jsp&mid=WC0b01ac058002956c
    • (2011) Official Journal of the European Union C 73/01
  • 33
    • 84881102185 scopus 로고    scopus 로고
    • Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use
    • Trojahn Kølle SF, RS Oliveri, PV Glovinski, M Kirchhoff, AB Mathiasen, JJ Elberg, PS Andersen, KT Drzewiecki and A Fischer-Nielsen. (2013). Pooled human platelet lysate versus fetal bovine serum-investigating the proliferation rate, chromosome stability and angiogenic potential of human adipose tissue-derived stem cells intended for clinical use. Cytotherapy 15:1086-1097.
    • (2013) Cytotherapy , vol.15 , pp. 1086-1097
    • Trojahn Kølle, S.F.1    Oliveri, R.S.2    Glovinski, P.V.3    Kirchhoff, M.4    Mathiasen, A.B.5    Elberg, J.J.6    Andersen, P.S.7    Drzewiecki, K.T.8    Fischer-Nielsen, A.9
  • 34
    • 84899757858 scopus 로고    scopus 로고
    • Inactivated human platelet lysate with psoralen: A new perspective for mesenchymal stromal cell production in good manufacturing practice conditions
    • Castiglia S, K Mareschi, L Labanca, G Lucania, M Leone, F Sanavio, L Castello, D Rustichelli, E Signorino, et al. (2014). Inactivated human platelet lysate with psoralen: a new perspective for mesenchymal stromal cell production in Good Manufacturing Practice conditions. Cytotherapy 16:750-763.
    • (2014) Cytotherapy , vol.16 , pp. 750-763
    • Castiglia, S.1    Mareschi, K.2    Labanca, L.3    Lucania, G.4    Leone, M.5    Sanavio, F.6    Castello, L.7    Rustichelli, D.8    Signorino, E.9
  • 37
    • 48249116583 scopus 로고    scopus 로고
    • Validation of analytical procedures: text and methodology Q2 (R1)
    • International Conference on Harmonization (ICH). Harmonised Tripartite Guideline. Validation of analytical procedures: text and methodology Q2 (R1). (2005). Available at http://www.ich.org/products/guidelines/quality/article/qualityguidelines.html
    • (2005) Harmonised Tripartite Guideline
  • 40
    • 84900419750 scopus 로고    scopus 로고
    • Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use
    • Gálvez P, B Clares, M Bermejo, A Hmadcha and B Soria. (2014). Standard requirement of a microbiological quality control program for the manufacture of human mesenchymal stem cells for clinical use. Stem Cells Dev 23:1074-1083.
    • (2014) Stem Cells Dev , vol.23 , pp. 1074-1083
    • Gálvez, P.1    Clares, B.2    Bermejo, M.3    Hmadcha, A.4    Soria, B.5
  • 42
    • 84877938781 scopus 로고    scopus 로고
    • Clinicalgrade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: Standardization of immune quality controls
    • Menard C, L Pacelli, G Bassi, J Dulong, F Bifari, I Bezier, J Zanoncello, M Ricciardi, M Latour, et al. (2013). Clinicalgrade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. Stem Cells Dev 22:1789-1801.
    • (2013) Stem Cells Dev , vol.22 , pp. 1789-1801
    • Menard, C.1    Pacelli, L.2    Bassi, G.3    Dulong, J.4    Bifari, F.5    Bezier, I.6    Zanoncello, J.7    Ricciardi, M.8    Latour, M.9
  • 43
    • 84881092225 scopus 로고    scopus 로고
    • Immunological characterization of multipotent mesenchymal stromal cells-The international society for cellular therapy (ISCT) working proposal
    • Krampera M, J Galipeau, Y Shi, K Tarte, Sensebe L; MSC Committee of the International Society for Cellular Therapy (ISCT). (2013). Immunological characterization of multipotent mesenchymal stromal cells-The International Society for Cellular Therapy (ISCT) working proposal. Cytotherapy 159:1054-1061.
    • (2013) Cytotherapy , vol.159 , pp. 1054-1061
    • Krampera, M.1    Galipeau, J.2    Shi, Y.3    Tarte, K.4    Sensebe, L.5
  • 44
    • 0347627149 scopus 로고    scopus 로고
    • Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells
    • Stenderup K, J Justesen, C Clausen and M Kassem. (2003). Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 33:919-926.
    • (2003) Bone , vol.33 , pp. 919-926
    • Stenderup, K.1    Justesen, J.2    Clausen, C.3    Kassem, M.4
  • 46
    • 35148856663 scopus 로고    scopus 로고
    • Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms
    • Bernardo ME, N Zaffaroni, F Novara, AM Cometa, MA Avanzini, A Moretta, D Montagna, R Maccario, R Villa, et al. (2007). Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res 67:9142-9149.
    • (2007) Cancer Res , vol.67 , pp. 9142-9149
    • Bernardo, M.E.1    Zaffaroni, N.2    Novara, F.3    Cometa, A.M.4    Avanzini, M.A.5    Moretta, A.6    Montagna, D.7    MacCario, R.8    Villa, R.9
  • 48
    • 79961138790 scopus 로고    scopus 로고
    • Largescale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells
    • Ben-David U, Y Mayshar and N Benvenisty. (2011). Largescale analysis reveals acquisition of lineage-specific chromosomal aberrations in human adult stem cells. Cell Stem Cell 9:97-102.
    • (2011) Cell Stem Cell , vol.9 , pp. 97-102
    • Ben-David, U.1    Mayshar, Y.2    Benvenisty, N.3
  • 49
    • 84855510030 scopus 로고    scopus 로고
    • Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells
    • Sensebé L, K Tarte, J Galipeau, M Krampera, I Martin, DG Phinney, Y Shi; MSC Committee of the International Society for Cellular Therapy. (2012). Limited acquisition of chromosomal aberrations in human adult mesenchymal stromal cells. Cell Stem Cell 10:9-10.
    • (2012) Cell Stem Cell , vol.10 , pp. 9-10
    • Sensebé, L.1    Tarte, K.2    Galipeau, J.3    Krampera, M.4    Martin, I.5    Phinney, D.G.6    Shi, Y.7
  • 50
    • 84901705554 scopus 로고    scopus 로고
    • Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols
    • Capelli C, O Pedrini, G Cassina, O Spinelli, S Salmoiraghi, J Golay, A Rambaldi, U Giussani and M Introna. (2014). Frequent occurrence of non-malignant genetic alterations in clinical grade mesenchymal stromal cells expanded for cell therapy protocols. Haematologica 99:e94-e97.
    • (2014) Haematologica , vol.99 , pp. e94-e97
    • Capelli, C.1    Pedrini, O.2    Cassina, G.3    Spinelli, O.4    Salmoiraghi, S.5    Golay, J.6    Rambaldi, A.7    Giussani, U.8    Introna, M.9
  • 51
    • 84878611378 scopus 로고    scopus 로고
    • Risk of tumorigenicity in mesenchymal stromal cell-based therapies-bridging scientific observations and regulatory viewpoints
    • Barkholt L, E Flory, V Jekerle, S Lucas-Samuel, P Ahnert, L Bisset, D Büscher, W Fibbe, A Foussat, et al. (2013). Risk of tumorigenicity in mesenchymal stromal cell-based therapies-bridging scientific observations and regulatory viewpoints. Cytotherapy 15:753-759.
    • (2013) Cytotherapy , vol.15 , pp. 753-759
    • Barkholt, L.1    Flory, E.2    Jekerle, V.3    Lucas-Samuel, S.4    Ahnert, P.5    Bisset, L.6    Büscher, D.7    Fibbe, W.8    Foussat, A.9
  • 52
    • 84886630589 scopus 로고    scopus 로고
    • Human adipose stromal cells (ASC) for the regeneration of injured cartilage display genetic stability after in vitro culture expansion
    • Neri S, P Bourin, J-A Peyrafitte, L Cattini, A Facchini and E Mariani. (2013). Human adipose stromal cells (ASC) for the regeneration of injured cartilage display genetic stability after in vitro culture expansion. PLoS One 8:e77895.
    • (2013) PLoS One , vol.8 , pp. e77895
    • Neri, S.1    Bourin, P.2    Peyrafitte, J.-A.3    Cattini, L.4    Facchini, A.5    Mariani, E.6
  • 53
    • 84884922980 scopus 로고    scopus 로고
    • Genomic alterations in human umbilical cord-derived mesenchymal stromal cells call for stringent quality control before any possible therapeutic approach
    • Borghesi A, MA Avanzini, F Novara, M Mantelli, E Lenta, V Achille, RM Cerbo, C Tzialla, S Longo, et al. (2013). Genomic alterations in human umbilical cord-derived mesenchymal stromal cells call for stringent quality control before any possible therapeutic approach. Cytotherapy 15:1362-1373.
    • (2013) Cytotherapy , vol.15 , pp. 1362-1373
    • Borghesi, A.1    Avanzini, M.A.2    Novara, F.3    Mantelli, M.4    Lenta, E.5    Achille, V.6    Cerbo, R.M.7    Tzialla, C.8    Longo, S.9
  • 54
    • 34247589774 scopus 로고    scopus 로고
    • Cytogenetic guidelines and quality assurance: A common European framework for quality assessment for constitutional and acquired cytogenetic investigations
    • Hastings RJ, S Cavani, FD Bricarelli, PC Patsalis, U Kristoffersson; ECA PWG Co-ordinators. (2007). Cytogenetic Guidelines and Quality Assurance: a common European framework for quality assessment for constitutional and acquired cytogenetic investigations. Eur J Hum Genet 15:525-527.
    • (2007) Eur J Hum Genet , vol.15 , pp. 525-527
    • Hastings, R.J.1    Cavani, S.2    Bricarelli, F.D.3    Patsalis, P.C.4    Kristoffersson, U.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.